COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma

Trial Profile

COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Ibandronic acid; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms COMPARE
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2010 Results reported at the 15th Congress of the European Haematology Association in June 2010.
    • 23 Feb 2010 Actual initiation date (1 Jan 2006) added as reported by Roche record.
    • 23 Feb 2010 Status changed from recruiting to completed as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top